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Vinod P. balachandran1,2,3, marta Łuksza4, Julia N. Zhao1,2,3, Vladimir makarov5,6, John Alec moral1,2,3, Romain Remark7, 
brian Herbst2, Gokce Askan2,8, Umesh bhanot8, Yasin Senbabaoglu9, Daniel K. Wells10, Charles Ian Ormsby Cary10, 
Olivera Grbovic-Huezo2, marc Attiyeh1,2, benjamin medina1, Jennifer Zhang1, Jennifer Loo1, Joseph Saglimbeni2,  
mohsen Abu-Akeel9, Roberta Zappasodi9, Nadeem Riaz6,11, martin Smoragiewicz12, Z. Larkin Kelley13,14, Olca basturk8, 
Australian Pancreatic Cancer Genome Initiative*, mithat Gönen15, Arnold J. Levine4, Peter J. Allen1,2, Douglas T. Fearon13,14, 
miriam merad7, Sacha Gnjatic7, Christine A. Iacobuzio-Donahue2,5,8, Jedd D. Wolchok3,9,16,17,18, Ronald P. Dematteo1,2, 
Timothy A. Chan3,5,6,11, benjamin D. Greenbaum19, Taha merghoub3,9,18§ & Steven D. Leach1,2,5,20§
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 
7% of patients surviving past 5 years. T-cell immunity has been 
linked to the exceptional outcome of the few long-term survivors1,2, 
yet the relevant antigens remain unknown. Here we use genetic, 
immunohistochemical and transcriptional immunoprofiling, 
computational biophysics, and functional assays to identify T-cell 
antigens in long-term survivors of pancreatic cancer. Using whole-
exome sequencing and in silico neoantigen prediction, we found 
that tumours with both the highest neoantigen number and the 
most abundant CD8+ T-cell infiltrates, but neither alone, stratified 
patients with the longest survival. Investigating the specific 
neoantigen qualities promoting T-cell activation in long-term 
survivors, we discovered that these individuals were enriched in 
neoantigen qualities defined by a fitness model, and neoantigens 
in the tumour antigen MUC16 (also known as CA125). A neoantigen 
quality fitness model conferring greater immunogenicity to 
neoantigens with differential presentation and homology to 
infectious disease-derived peptides identified long-term survivors 
in two independent datasets, whereas a neoantigen quantity model 
ascribing greater immunogenicity to increasing neoantigen number 
alone did not. We detected intratumoural and lasting circulating 
T-cell reactivity to both high-quality and MUC16 neoantigens in 
long-term survivors of pancreatic cancer, including clones with
specificity to both high-quality neoantigens and predicted cross-
reactive microbial epitopes, consistent with neoantigen molecular 
mimicry. Notably, we observed selective loss of high-quality and
MUC16 neoantigenic clones on metastatic progression, suggesting
neoantigen immunoediting. Our results identify neoantigens
with unique qualities as T-cell targets in pancreatic ductal
adenocarcinoma. More broadly, we identify neoantigen quality as a 
biomarker for immunogenic tumours that may guide the application
of immunotherapies.
To define the importance of neoantigens in pancreatic ductal 
 adenocarcinoma (PDAC), we compared stage-matched cohorts of 
treatment-naive, surgically resected, rare long-term survivors (LTSs, 
median survival 6 years, n = 82) to short-term survivors with a more 
typical poor outcome (median survival 0.8 years, n = 68; Memorial 
Sloan Kettering Cancer Center (MSKCC) cohort; Fig. 1a, Extended 
Data Fig. 1a–e). Using nine-parameter multiplexed immunohisto-
chemistry3 and immunofluorescence in tissue microarrays, we found 
greater  densities of CD8+ T cells (3-fold), cytolytic CD8+ cells (12-fold), 
mature  dendritic cells, regulatory T cells, macrophages, and decreased 
numbers of CD4+ T cells in tumours of LTSs, yet no differences in 
1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, 
New York, New York, USA. 3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 4The Simons Center for Systems Biology, Institute for 
Advanced Study, Princeton, New Jersey, USA. 5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 6Immunogenomics and Precision 
Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 7Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York,  
New York, USA. 8Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 9Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA. 
10Parker Institute for Cancer Immunotherapy, San Francisco, California, USA. 11Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 12Cancer 
Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK. 13Cold Spring Harbor Laboratory, New York, New York, USA. 14Department of Microbiology 
and Immunology, Weill Cornell Medical School, New York, New York, USA. 15Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 16Melanoma and 
Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 17Weill Cornell Medical College, Cornell University, New York, New 
York, USA. 18Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 19Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, 
Oncological Sciences, and Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 20Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire, USA.
*Lists of participants and their affiliations appear in the online version of this paper. 
§These authors jointly supervised this work.
edb
4.5%
95.5% 94.7%
5.3%
Short term Long term
Shared with adjacent
Unique to tumour
a
Years
Long term
Short term
P < 0.0001
HR = 0.18 (0.11–0.31)
50
100
5 10
0
0
S
ur
vi
va
l (
%
)
Median 0.8 years
n = 68
Median 6 years
n = 82
N
o.
 o
f C
D
3+
C
D
8+
ce
lls
 p
er
 m
m
2
2,000
80
100
500
1,500
1,000
40
60
20
0
Short
term
n = 45
Long
term
n = 51
78
28
P = 0.0008
N
o.
 o
f C
D
3+
C
D
8+
 
gr
an
zy
m
e 
B
+
 c
el
ls
 p
er
 m
m
2
25
125
25
0
Short
term
n = 45
Long
term
n = 51
12
1
P < 0.0001
Short
term
n = 30
Long
term
n = 30
C
lo
na
lit
y
0.12
0.0
0.25
P = 0.04
C
lo
na
lit
y
0.1
0.2
0
0.4
0.3
Adjacent
pancreas
n = 60
Tumour
n = 60
P < 0.0001P < 0.0001
T 
ce
lls
 o
f
se
q
ue
nc
ed
 c
el
ls
 (%
)
10
20
0
40
30
Adjacent
pancreas
n = 60
Tumour
n = 60
c
More
polyclonal
More
oligoclonal
More
polyclonal
More
oligoclonal
Figure 1 | Pancreatic cancer survivors display enhanced T-cell 
immunity. a, Survival of MSKCC cohort patients. HR, hazard  
ratio. b, Quantification of CD8+ T cells using multiplexed 
immunohistochemistry. c, d, T-cell frequency and repertoire clonality 
(c) and clonal overlap (d) in tumour and matched adjacent normal
pancreatic tissues, determined by TCR Vβ sequencing. e, Intratumoural 
T-cell repertoire clonality in tumours of short- and long-term survivors 
of PDAC. Horizontal bars indicate median values. n is the number
of biologically independent samples in individual patients. P values
were determined using a log-rank test (a), a two-tailed Mann–Whitney 
U-test (b), a two-tailed paired (c) and a two-tailed unpaired Student’s 
t-test (e).
B cells and major histocompatibility complex (MHC) class I+ cells (Fig. 1b, 
Extended Data Fig. 2a). Transcriptomic profiling revealed an immu-
nogenic microenvironment in tumours of LTSs, with upregulation of 
molecular markers of dendritic cells4, and antigen experience (PD-1 
and TIGIT)5, as well as downregulation of the  immunosuppressive 
marker STAT3 (Extended Data Fig. 2b). Sequencing of the T-cell 
receptor (TCR) Vβ chain demonstrated that intratumoural T cells 
were increased fivefold compared to matched adjacent non-tumour 
pancreatic tissue and were markedly polyclonal (Fig. 1c). Notably, more 
than 94% of intratumoural T-cell clones were unique to tumours, con-
sistent with tumour  specificity (Fig. 1d). Additionally, in unselected 
patients, flow cytometry on intratumoural T cells revealed activation 
and  memory marker upregulation compared to draining lymph node 
and blood T cells, consistent with antigen specificity (Extended Data 
Fig. 2c). Finally, tumours of LTSs exhibited greater TCR repertoire diver-
sity (Fig. 1e). The association of activated CD8+ T cells and survival was 
independent of clinicopathological factors and adjuvant chemotherapy 
(Extended Data Fig. 2d). Collectively, tumours of LTSs exhibited an 
activated, polyclonal, tumour-specific T-cell infiltrate, suggesting 
differential antigenic targets.
To determine the neoantigen frequency in PDACs, we performed 
whole-exome sequencing on macrodissected tumour islands. We 
detected a median of 38 predicted neoantigens per tumour6 (Extended 
Data Fig. 3a, Supplementary Table 1). Notably, patients with both 
the highest predicted neoantigen number and either the  greatest 
CD3+CD8+, or polyclonal T-cell repertoire, but neither alone, 
exhibited the longest survival (median survival not reached, Fig. 2a, 
Extended Data Fig. 3b). We corroborated these findings using a second 
 neoantigen prediction algorithm7 (Fig. 2a, Extended Data Fig. 3b, c). 
This association of higher neoantigen quantity and CD8+ T-cell 
infiltrate with survival was independent of adjuvant chemotherapy 
(Extended Data Fig. 3d). Furthermore, we found that higher neoantigen 
quantity and CD8+ T-cell infiltrate together exhibited the strongest 
association with survival, with other genomic and immune  parameters 
showing weak or no association with survival8 (Extended Data 
Fig. 4a–d). Together, these data suggest that neoantigen immunogenicity 
and quality, and not purely quantity, correlate with survival.
Next, we investigated neoantigen qualities that modulate differen-
tial immunogenicity. The theory of molecular mimicry postulates that 
TCRs that can recognize pathogenic antigens can also recognize non- 
pathogenic antigens, which has been documented in autoimmunity9  
but not in the cancer context. We theorized that neoantigen homology 
to infectious disease-derived epitopes, which are recognized by the 
human TCR repertoire, can serve as a partial surrogate for differential 
neoantigen immunogenicity or ‘non-selfness’. This hypothesis does not 
assume any associations between pre-existing antimicrobial immunity 
and survival, but rather aims to develop a strategy to identify candi-
date neoantigens based on defined immunogenic pathogen-derived 
epitopes. To test this hypothesis, we developed neoantigen quality and 
quantity models (Extended Data Fig. 5a, b). For each neoantigen in the 
quality model, we derived sequence alignment scores to human infec-
tious disease-derived, class I-restricted peptide sequences with positive 
immune assays (hereby referred to as ‘microbial’) from the Immune 
Epitope Database (IEDB, Supplementary Table 2). We then inferred its 
probability of TCR recognition using a nonlinear logistic dependence 
on alignment score, and calculated quality scores by amplifying 
these binding probabilities by inferred relative wild-type and mutant 
 peptide-MHC class I affinities (Extended Data Fig. 5a, b). For the 
quantity model, the neoantigen score equalled the total number of 
neoantigens within a clone. Using an evolutionary model, we inter-
preted the score of a clone as calculated by each model as its fitness 
cost due to immune interactions10. We then recreated the clonal tree 
structure for each tumour based on mutant allele frequencies, and pro-
jected the change to the effective cancer cell population size of each 
tumour. Of these models, the quality model, but not the quantity model, 
 significantly stratified short- and long-term survivors independent of 
confounding factors and adjuvant chemotherapy (Fig. 2b, Extended 
Data Fig. 6a). Notably, all tumours with the highest neoantigen load in 
combination with the most abundant CD8+ T-cell infiltrates  harboured 
high-quality neoantigens (Extended Data Fig. 3e). Testing these models 
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Figure 2 | Neoantigen quality is prognostic of survival. a, Survival of 
patients with tumours harbouring greater than the median number of both 
neoantigens (neoantigenhi) and CD3+CD8+ cells (CD3-CD8hi), compared 
to all other patients (rest), as determined by the MSKCC (left) and pVAC-
Seq (right) neoantigen prediction pipelines. b, Patient survival stratified 
by neoantigen quality and quantity in the MSKCC (left) and ICGC (right) 
cohorts. OS, overall survival. n is the number of biologically independent 
samples in individual patients. P values were determined using a log-rank 
test.
in a larger cohort unselected by survival (International Cancer Genome 
Consortium (ICGC); n = 166), neoantigen quality, but not quantity, was 
significantly prognostic of survival and independent of confounding 
variables (Fig. 2b, Extended Data Fig. 6b, c), with a stable association 
with survival in subsampled datasets in both cohorts (Extended Data 
Fig. 7a, b). We conclude that neoantigen quality is a biomarker of 
survival in PDAC.
Recent data have shown that T-cell-recognized neoantigens can be 
selectively lost from the tumour cell population by either mutant allelic 
loss or overall reduced gene expression11. Consistently, genes with 
high-quality neoantigens evidenced a modest trend to lower mRNA 
expression compared to gene expression in the absence of high-quality 
neoantigens (Fig. 3a). To explore further possible in vivo high-quality 
neoantigen immunoediting, we examined neoantigen clonal dynamics 
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Figure 3 | Neoantigen and cross-reactive microbial peptide T cells 
detected in blood and tumours. a, Left, gene expression in the presence 
(red) or absence (grey) of high-quality neoantigenic mutations. x axis, 
genes; shaded circles, biologically independent samples in individual 
patients (n = 30). Right, median non-neoantigenic and neoantigenic 
expression. All high-quality neoantigenic genes with available mRNA 
expression are shown. b, Metastatic propagation of all clones in the 
primary tumour stratified by neoantigen quality. Mutant allele frequencies 
in matched primary–metastatic tumours (left) and metastatic tumours 
alone (right) are shown in biologically independent samples in one patient. 
MAF, mutant allele frequency; M, metastasis; P, primary tumour. 
c, d, Peripheral blood mononuclear cells (PBMCs) pulsed with no (N), 
wild-type control (WT), cross-reactive (CR), and high-quality neo (M) 
peptides (n = 7). c, CD8+ T-cell expansion and degranulation. d, Clonal 
overlap of expanded T-cell clones in c and archival tumours by TCR Vβ 
sequencing. Arrows indicate clones in archival primary tumours with rank 
frequencies. Venn diagrams show the number of T-cell clones expanding 
with mutant peptides, with cross-reactive peptides, their respective 
clonal overlap, and clonal overlap with archival primary tumours. Note 
the presence of clones recognizing both neopeptides and cross-reactive 
peptides in archival tumours. Years surviving after surgery are shown for 
each individual patient. AWD, alive with disease; NED, no evidence of 
disease. Horizontal bars indicate median values, error bars represent the 
s.e.m. n is the number of biologically independent samples in individual
patients in a and c. P values were determined using a two-tailed Student’s 
t-test (a), a two-tailed Mann–Whitney U-test (b), a one-way analysis
of variance (ANOVA) with Tukey’s multiple comparison test (c) and as 
described in the Methods (d).
on primary-to-metastatic tumour progression in one patient obtained 
through rapid autopsy. Of the three clones in the primary tumour, both 
clones with high-quality neoantigens were lost in multiple metastatic 
samples, in contrast to the clone with a low-quality neoantigen that was 
propagated to multiple metastatic sites (Fig. 3b, Extended Data Fig. 1f). 
These findings suggest differential immune fitness of clones bearing 
high- versus low-quality neoantigens within the same primary tumour.
Next, we sought to detect in vivo T-cell responses to high- quality 
neoantigens. We identified 7 very long-term survivors of PDAC 
(median overall survival 10.5 years) that normally account for less 
than 2% of all patients with PDAC (Extended Data Fig. 1g), and 
pulsed their peripheral blood mononuclear cells (PBMCs) with 
antigens predicted by the quality model. Notably, we observed selec-
tive CD8+ T-cell expansion and degranulation (as measured by 
CD107a expression) to neopeptides and their homologous infectious 
disease-derived peptides (deemed the ‘cross-reactive’ peptide relative to 
a neoantigen) but not to their wild-type peptides (Fig. 3c, Extended Data 
Fig. 8a, b, Supplementary Table 3). Moreover, in all patients, identical 
TCR clones were significantly expanded to both the neopeptides and 
cross-reactive peptides (Fig. 3d). In five out of seven patients, we iden-
tified neoantigen and microbial cross-reactive peripheral T-cell clones, 
and in seven out of seven patients high-quality neoantigen-reactive 
T-cell clones that were also present in their respective archival primary 
tumours. Patient 3, alive and disease-free 12 years after primary tumour 
removal, illustrated the most extreme instance—15 neoantigen and
microbial cross-reactive T-cell clones that persisted in the peripheral 
blood were found in the primary tumour, including the most frequent 
intratumoural T-cell clone with a rank frequency of 6.2% (Fig. 3d).
We conclude that our  quality model identifies bona fide neoantigens 
targeted by T cells, and that tumour-infiltrating T cells can cross- 
reactively recognize both cancer neoantigens and homologous
non-cancer microbial antigens.
In exploring whether select genetic loci or ‘immunogenic hotspots’ 
were preferentially enriched for neoantigens, we detected four loci har-
bouring neoantigens in more than 15% of all patients, with one locus 
preferentially enriched in LTSs: the tumour antigen MUC16, which is a 
common ovarian cancer biomarker and an established T-cell immuno-
therapy target12 (Fig. 4a). In tumours of LTSs, we found a fourfold 
higher frequency of MUC16 neoantigens and several MUC16 neo-
antigens in the same tumour, whereas non-antigenic MUC16 mutation 
frequency was no different (Fig. 4b, c, Extended Data Fig. 9a). Only 
one patient with MUC16 neoantigens had a hypermutated phenotype 
(more than 500 mutations), and exclusion of this patient did not alter 
the results (Fig. 4c). Supporting possible in vivo anti-MUC16 immu-
nity, tumours in LTSs had lower levels of mRNA (6.6-fold),  protein, 
and a lower mutant allele frequency (4-fold) in non- hypermutated 
tumours compared to short-term survivors (Extended Data Fig. 9b). 
Consistently, the pVAC-Seq pipeline identified MUC16 as the most 
common locus generating neoantigens, after the frequently mutated 
oncogenes (KRAS and TP53) (Extended Data Fig. 9c). We found no 
differences between the two cohorts in cell-autonomous regulators 
of MUC16 expression, mediators of MUC16-dependent effects on 
tumour progression, other mucin or tumour antigen expression, or 
evidence of MUC16 mutations altering RNA or protein expression13–16 
(Extended Data Fig. 9d). One interpretation of these results is that 
MUC16 neoantigen-specific T-cell immunity induces immunoediting 
of MUC16-expressing clones in primary tumours, and prolongs 
 survival, given the cell-autonomous roles of MUC16 in promoting 
metastases14,16. Notably, MUC16 protein expression was low yet not 
absent in the tumours of LTSs, indicating antigen availability, and 
mutations did not affect cell intrinsic expression (Extended Data 
Figs 9e, 10a–c). Consistent with possible MUC16 immunoediting, 
MUC16 neoantigens in primary tumours had complete neoantigenic 
mutational loss in matched metastases (n = 10), in contrast to MUC16 
non-neoantigenic mutations that demonstrated mutation enrichment 
on metastatic progression (Fig. 4d, Extended Data Fig. 1f). MUC16 
was also the only locus recurrently harbouring neoantigens in both 
MSKCC and ICGC cohorts, outside of the most frequently mutated 
genes (oncogenes KRAS, TP53; largest human gene TTN) (Extended 
Data Fig. 9c). Although the propensity to generate MUC16 neoantigens 
may be related to its large size, we did not detect trends towards neo-
antigen formation based on gene size alone across cohorts or pipelines. 
Additionally, as the number of patients with MUC16 neoantigens in the 
LTS cohort was small, validation in a larger LTS dataset is warranted. 
Hence MUC16 is a candidate immunogenic hotspot in PDAC.
We next stimulated peripheral blood from two LTSs (both dis-
ease-free 8 years after surgery) with predicted MUC16 neoantigens. In 
both patients, we observed CD8+ T-cell expansion and degranulation, 
with expanded clones detected in archival surgically resected primary 
tumours (Fig. 4e, Extended Data Fig. 9f). We confirmed peripheral 
blood CD8+ T-cell recognition of two additional MUC16  neoantigen–
MHC complexes using peptide–MHC multimers in human leukocyte 
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Figure 4 | MUC16 is a neoantigenic hotspot in survivors of pancreatic 
cancer. a, Genes with neoantigens in more than 15% of patients. MT-NDS 
is also known as MTND5P1. b, MUC16 neoantigen frequency. c, Number 
of MUC16 neoepitopes per patient. Short term n = 32, long term n = 26 
in a–c. d, Metastatic propagation of all clones in the primary tumour 
stratified by the presence or absence of MUC16 neoantigens. Mutant allele 
frequencies in matched primary–metastatic tumours (left) and metastatic 
tumours alone (far right) are shown in biologically independent samples 
in four patients. e, CD8+ T-cell degranulation in PBMCs pulsed with no 
peptide (none), control wild-type peptide (WT), and MUC16 neopeptide 
(mutant). Data in e are representative of two independent experiments 
with similar results. n is the number of biologically independent samples 
in individual patients. Horizontal bars indicate median values, error bars 
represent the s.e.m. P values were determined using a two-sided χ2 test  
(a, b), a two-tailed Mann–Whitney U-test (c, d) and a two-way ANOVA 
with Tukey’s multiple comparison test (e).
antigen (HLA)-matched healthy donors (Extended Data Fig. 8c), con-
sistent with putative MUC16 neoantigen binding by the human TCR 
repertoire. Hence we present evidence of in vivo T-cell reactivity to neo-
antigens in the tumour antigen MUC16, with lasting MUC16-specific 
T-cell immunity in survivors of PDAC.
Our results do not indicate causal associations of pre-existing micro-
bial and anti-tumour immunity in LTSs. Instead, our data suggest that 
embedding microbial homology in the context of our neoantigen 
quality model can help to create an effective surrogate for immuno-
genic neoantigens. We posit two non-mutually exclusive mechanisms 
to explain these findings. The first is that although the naive human 
TCR repertoire is theoretically vast, the observed TCR recombination 
products are notably restricted17, possibly representing sculpting of the 
TCR recombination space under the evolutionary selection pressures 
of pathogens, thereby skewing the repertoire to recognize their com-
mon protein features. The second is that as microbial antigens are by 
definition non-self sequences, enriched with documented human T-cell 
clones surviving thymic selection, homologous tumour neo antigens 
are similarly non-self sequences enriched with bona fide human T-cell 
clones. However, given recent evidence of intratumoural  bacterial 
polarization of T-cell phenotypes18, and microbial dependence of 
immunotherapy efficacy9, whether homology to patient-derived micro-
biomes enhances relevant neoantigen identification remains unknown 
yet timely. Notably, we identified no associations with survival when 
neoantigen quality was calculated using alignment to immunogenic 
allergy or autoimmune-derived IEDB peptides (Extended Data Fig. 7c). 
However, the significant size discrepancy between the number of 
infectious disease-derived (Supplementary Table 2) and allergy or 
autoimmune-derived (Supplementary Table 4) peptides would  warrant 
confirmation of these results in a larger allergy or autoimmune peptide 
dataset.
Although viral-specific T cells have been detected in human 
tumours19, the presence of identical circulating and intratumoural 
T-cell clones reactive to both high-quality neoantigens and infec-
tious disease-derived sequences offers proof-of-principle of neoanti-
genic molecular mimicry in a cancer context. Although patients with
high-quality neoantigen tumours exhibited prolonged survival, it
remains unproven whether these cross-reactive T-cell clones  contribute 
to this outcome, or whether this reflects the degeneracy of the human 
TCR repertoire.
Our results provide insight into the heterogeneous immuno-
biology of PDAC, a presumed poorly immunogenic and checkpoint 
 blockade-refractory tumour, demonstrating that neoantigens may 
be T-cell targets in LTSs. We propose that neoantigen quality, and 
not merely quantity, modulates immunogenicity, clonal fitness, and 
immunoselection during tumour evolution, with neoantigens in 
immun ogenic residues such as MUC16 emerging as apparent hotspots. 
Our data suggest that neoantigen-specific immunity gained during 
 primary tumour outgrowth could be associated with decreased relapse 
and prolonged survival, comparable to classical mouse studies of prior 
tumour exposure protecting against tumour rechallenge20. Our findings 
support the development of strategies to harness neoantigen- specific 
immunity to treat checkpoint blockade-refractory cancers, and the iden-
tification of immunogenic hotspots for directed neoantigen targeting.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Data reporting. No statistical methods were used to predetermine sample size. 
The investigators were not blinded to allocation during experiments and outcome 
assessment.
Patient samples. MSKCC PDAC cohort. All tissues were collected at MSKCC 
following study protocol approval by the MSKCC Institutional Review Board. 
Informed consent was obtained for all patients. The study was in strict  compliance 
with all institutional ethical regulations. All tumour samples were surgically 
resected primary pancreatic ductal adenocarcinomas. Patients treated with neoad-
juvant therapy were excluded. All tumours were subjected to pathological re-review 
and histological confirmation by two expert PDAC pathologists before analysis. 
LTSs were defined as patients with overall survival of > 3 years from surgery, short-
term survivors as patients with survival > 3 months and < 1 year from surgery, to 
exclude perioperative mortalities.
ICGC cohort. Clinical characteristics of the ICGC cohort have been described 
previously21.
Rapid autopsy cohort. Primary and metastatic tumour samples were collected 
posthumously from four patients as part of the Gastrointestinal Cancer Rapid 
Medical Donation program at Johns Hopkins Hospital22. Informed consent was 
obtained from all subjects. This program was deemed in accordance with the 
Health Insurance Portability and Accountability Act and the study protocol was 
approved by the Johns Hopkins Hospital Institutional Review Board. The study 
was in strict compliance with all institutional ethical regulations.
Tissue microarray. Tissue microarrays were constructed from tumour and 
 adjacent non-tumour cores from formalin-fixed, paraffin-embedded tissue 
blocks in short- (n = 45 tumours, 5 normal tissue) and long-term (n = 51 tumours, 
5 normal tissue) survivors of PDAC. Histology sections were reviewed by two 
expert PDAC pathologists and the most representative areas were selected and 
marked on haematoxylin and eosin slides. 1 mm diameter cores were sampled from 
three different tumour regions per patient using an automated TMA Grand Master 
(Perkin Elmer). 5-μ m sections were prepared from tissue microarray blocks for 
immunohistochemistry. Patient subsets were randomly selected to undergo tissue 
microarray construction.
Immunohistochemistry. Human-specific antibodies to MUC16 (clone OCT125, 
dilution 1:130), WT1 (clone CAN-R9 (IHC)-56-2, dilution 1:30), and annexin 
A2 (ab54771, 5 μ g ml−1) were purchased from Abcam. Antibodies to MUC1 
(clone M695, dilution 1:100), and mesothelin (clone 5B2, dilution 1:50) were 
 purchased from Vector Laboratories. Immunohistochemistry was performed using 
 standard techniques. MUC16 expression was scored as described23. For each core, 
a cumulative MUC16 expression score was calculated as the product of a score 
for the  frequency of tumour cells expressing MUC16 (0–25% = 1; 26–50% = 2; 
51–75% = 3; 76–100% = 4) and a score for the intensity of staining (0 = negative; 
1 = weak; 2 = moderate; and 3 = strong). The median expression score across trip-
licate cores is reported as the final score for each patient.
Multiplexed consecutive immunohistochemistry on the same slide was 
 performed as described3. Tissue microarray slides were incubated overnight at 
37 °C. Then, paraffin was removed using xylene and the tissue rehydrated before 
incubation in antigen-retrieval solution at 95 °C for 45 min (pH 9 Target Retrieval 
Solution, Dako). After endogenous peroxidase inhibition and FcR blocking, 
 granzyme B was stained with anti-granzyme B monoclonal antibody (clone GrB-7, 
Dako) for 1 h at room temperature. After signal amplification with a horseradish 
peroxidase (HRP)-labelled polymer (Dako), the revelation was performed using 
3-amino-9-ethylcarbazole (AEC, Vector Laboratories). Then slides were immersed
in haematoxylin, rinsed in distilled water and mounted in aqueous-based mounting 
medium (Glycergel, Dako). After imaging using a whole-slide scanner, the slides 
were subjected to the Multiplexed Immunohistochemical Consecutive Staining 
on Single Slide protocol (MICSSS) and stained for T cells (CD3, clone 2GV6, 
Ventana and CD8, clone C8/144b, Dako), regulatory T cells (FoxP3, clone 236A/
E7, Abcam), B cells (CD20, clone L26, Dako), macrophages (CD68, clone KP1, 
Dako), mature dendritic cells (DC-LAMP, clone 1010E1.01, Novus Biologicals), 
MHC class I cells (HLA-ABC, clone EMR8-5, Abcam) and tumour cells (CK19, 
clone EP1580Y, Abcam).
Immunofluorescence. For CD4, FoxP3, and CK19 staining, sections were first
incubated with anti-CD4 (Ventana, 790-4423, 0.5 μ g ml−1) for 5 h, followed by
60 min incubation with biotinylated goat anti-rabbit IgG (Vector Laboratories, 
PK6101) at 1:200 dilution. The detection was performed with streptavidin–HRP 
D (part of DABMap kit, Ventana Medical Systems), followed by incubation with 
 tyramide Alexa Fluor 488 (Invitrogen, T20922) prepared according to the manu-
facturer’s instructions with predetermined dilutions. Next, slides were  incubated 
with anti-FoxP3 (Abcam, ab20034, 5 μ g ml−1) for 4 h, followed by a 60 min
 incubation with biotinylated horse anti-mouse IgG (Vector Labs, MKB-22258) at 
1:200  dilution. The detection was performed with streptavidin–HRP D (part of 
DABMap kit, Ventana Medical Systems), followed by incubation with tyramide 
Alexa Fluor 568 (Invitrogen, T20914) prepared according to the manufacturer’s 
instructions with predetermined dilutions. Finally, sections were incubated with 
anti-CK19 (Abcam, ab52625, 1 μ g ml−1) for 5 h, followed by a 60 min incuba-
tion with biotinylated goat anti-rabbit IgG (Vector, PK6101) at 1:200 dilution. 
The detection was performed with streptavidin–HRP D (part of DABMap kit, 
Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 
647 (Invitrogen, T20936) prepared according to the manufacturer’s instructions 
with predetermined dilutions. After staining, slides were counterstained with 
4′ ,6- diamidino-2-phenylindole (DAPI, Sigma Aldrich, D9542, 5 μ g ml−1) for 
10 min and coverslips mounted with Mowiol.
For CD3, CD8 and CK19 staining, slides were first incubated with anti-CD3 
(DAKO, A0452, 1.2 μ g ml−1) for 4 h, followed by a 60 min incubation with biotiny-
lated goat anti-rabbit IgG (Vector Labs, PK6101) at 1:200 dilution. The detection 
was performed with streptavidin–HRP D (part of DABMap kit, Ventana Medical 
Systems), followed by incubation with tyramide Alexa Fluor 488 (Invitrogen, 
T20922) prepared according to the manufacturer’s instructions with predeter-
mined dilutions. Next, slides were incubated with anti-CD8 (Ventana, 790-4460, 
0.35 μ g ml−1) for 5 h, followed by a 60 min incubation with biotinylated goat 
anti-rabbit IgG (Vector, PK6101) at 1:200 dilution. The detection was performed 
with streptavidin–HRP D (part of DABMap kit, Ventana Medical Systems), 
 followed by incubation with tyramide Alexa Fluor 568 (Invitrogen, T20914) 
 prepared according to the manufacturer’s instructions with predetermined 
 dilutions. Finally, sections were incubated with anti-CK19 (Abcam, ab52625, 
1 μ g ml−1) for 5 h, followed by 60 min incubation with biotinylated goat anti- 
rabbit IgG (Vector, PK6101) at 1:200 dilution. The detection was performed with 
 streptavidin–HRP D (part of DABMap kit, Ventana Medical Systems), followed 
by incubation with tyramide Alexa Fluor 647 (Invitrogen, T20936) prepared 
 according to the manufacturer’s instructions with predetermined dilutions. After 
staining, slides were counterstained with DAPI (Sigma Aldrich, D9542, 5 μ g ml−1) 
for 10 min and coverslips mounted with Mowiol.
Digital image processing and analysis. Tissue microarrays for each immuno-
histochemical stain were individually digitally scanned using Pannoramic Flash 
(3DHistech) with a 40× /0.95 numerical aperture (NA) objective. Image registra-
tion and alignment was performed using ImageJ (NIH). Regions of interest were 
drawn for each core and then transferred to others using CaseViewer (3DHistech). 
Each region from each scan was exported as a TIF file at full resolution (0.243 μ m 
per pixel). Images of the same core from multiple scans were stacked together 
and aligned using Linear Stack Alignment with SIFT algorithm from FIJI/ImageJ 
(NIH). Once aligned, the RGB images were colour deconvoluted to separate AEC 
and haematoxylin stainings and converted into eight-bit pseudo-fluorescent 
images. Individual immunohistochemical targets were sequentially assigned to 
fluorescent channels and subsequently merged. Haematoxylin staining was used 
to segment and count the number of nucleated cells in the core. After processing 
the images using background subtraction and median filter, staining was thres-
holded and split using Biovoxxel Watershed Irregular Features plugin. Regions of 
interest were drawn around each cell and matched to the signals from all other AEC 
stainings to count the number of positive cells for each staining. Total tissue area 
was measured by setting a very low threshold for haematoxylin images. For quanti-
fication, all nucleated cells were identified, followed by an intensity-based threshold 
determination of each target to identify positive cells. Triplicate cores were quanti-
fied followed by determination of the median number of cells per square millimetre 
of tissue (ImageJ, NIH). Quantification of cells detected using immunofluorescence 
was performed in a similar fashion. CD8+ T cells were defined as CD3+CD8+ cells, 
cytolytic CD8+ T cells as CD3+CD8+granzyme B+ cells, mature dendritic cells as 
DC-LAMP+ cells, regulatory T cells as CD3+FoxP3+ cells, macrophages as CD68+ 
cells, CD4+ T cells as both CD3+CD8− and CD4+ cells, B cells as CD20+ cells, and 
class-I expressing cells as MHC-I+ cells.
Nucleic acid extraction. MSKCC PDAC cohort. 10 μ m slides were cut from OCT-
embedded frozen tumour and matched normal tissues. Sections were brought to 
containers with 70% ethanol for OCT removal. After OCT removal, specimens 
were dissected for subsequent DNA and RNA extraction. For whole-exome
sequencing, tumour islands of > 70% cellularity were macrodissected based on 
expert PDAC pathological review, and DNA was extracted using the DNeasy kit. 
Total RNA from fresh frozen OCT-embedded tissues was extracted using TRIzol 
RNA Isolation Reagents (15596-026, Life Technologies).
Rapid autopsy cohort. Genomic DNA was extracted using standard phenol–chloro-
form extraction followed by precipitation in ethanol. Quantification was achieved 
by LINE assay. Tissue samples confirmed to be of high quality and  sufficient con-
centration were used for subsequent whole-exome sequencing.
Transcriptome analysis. Extracted RNA was qualified on an Agilent BioAnalyzer
and quantified by fluorometry (Ribogreen). Preparation of RNA for whole
transcriptome expression analysis was done using the WT Pico Reagent Kit 
(Affymetrix). Reverse transcription was initiated at the poly-A tail as well as 
throughout the entire length of RNA to capture both coding and multiple forms of 
non-coding RNA. RNA amplification was achieved using low-cycle PCR  followed 
by linear amplification using T7 in vitro transcription technology. The cRNA was 
then converted to biotinylated sense-strand DNA hybridization targets. The 
prepared target was hybridized to GeneChip Human Transcriptome Array 2.0 
(Affymetrix). Wash and scan was performed using the GeneChip Hybridization, 
Wash and Stain Kit using a Fluidics Station 450/250. Arrays were scanned using 
the GeneChip Scanner 3000. Data analysis for the array was done using Affymetrix 
Expression Console Software (SST-RMA algorithm to summarize the signal from 
array probesets). A dendritic cell signature was defined as described previously, 
using the genes CCL13, CCL17, CCL22, PPFIBP2, NPR1, HSD11B1, and CD209 
(also known as DC-SIGN)4. Patient subsets were randomly selected to undergo 
transcriptomic profiling.
TCR Vβ sequencing. Frozen tumour (short term n = 30, long term n = 30) 
and paired non-tumour adjacent pancreas tissue (short term n = 30, long term 
n = 30) samples were processed (Adaptive Biotechnologies). Genomic DNA was 
extracted according to the manufacturer’s instructions (QIAsymphony, Qiagen). 
The quantity and quality of extracted DNA was verified before sequencing. Using 
a standard quantity of input DNA, the TCR Vβ CDR3 regions were amplified and 
sequenced using the survey multiplexed PCR ImmunoSeq assay. The ImmunoSeq 
platform combines multiplex PCR with high-throughput sequencing to selectively 
amplify the rearranged complementarity-determining region 3 (CDR3) of the 
TCR,  producing fragments sufficiently long to identify the VDJ region  spanning 
each unique CDR3. 45 forward primers specific for TCR Vβ gene segments 
and 13 reverse primers specific to TCR Jβ gene segments were used (Adaptive 
Biotechnologies). Read lengths of 156 bp were obtained using the Illumina HiSeq 
System. The ImmunoSeq assay allows for quantitative assessment of both total 
and unique TCRs in a sample, as it uses a complete synthetic repertoire of TCRs 
to establish an amplification baseline and adjust the assay chemistry to correct for 
primer bias. Barcoded, spiked-in synthetic templates were also used to measure 
and correct for sequencing coverage and residual PCR bias. Output data were then 
filtered and clustered using the relative frequency ratio between similar clones and 
a modified nearest-neighbour algorithm, to merge closely related sequences and 
remove PCR and sequencing errors. The number of rearranged TCRs per diploid 
genome in the input material (total number of T cells) was estimated as described 
previously24. The frequency of T cells was determined as the total number of T 
cells per total number of sequenced cells in the input material. A T-cell clone was 
defined as a T cell with a unique TCR Vβ CDR3 amino acid sequence. Clonality 
was defined as (1 −  normalized entropy). Normalized entropy was calculated as 
the Shannon entropy divided by the logarithm of the number of unique productive 
(exonic) TCR sequences. Shannon entropy equals the clonal abundance of all pro-
ductive TCR sequences in the input material. For in vitro stimulated cells, clones 
with identical amino acid sequences that expanded > 2-fold on day 21 compared 
to day 0, and fulfilled the Fisher’s exact test and Storey’s Q value for false discov-
ery rate were defined as expanded. Data analysis was performed using Adaptive 
Biotechnologies ImmunoSeq Analyzer (Analyzer 3.0).
Whole-exome sequencing. For all MSKCC PDAC patients, 500 ng of genomic 
DNA was fragmented to a target size of 150–200 bp on the Covaris LE220 system. 
Barcoded libraries (Kapa Biosystems) were subjected to exon capture by hybridi-
zation using the SureSelect Human All Exon 51MB V4 kit (Agilent). DNA libraries 
were subsequently sequenced on a HiSeq 4000 (Illumina) in a Paired End 100/100, 
using the TruSeq SBS Kit v3 (Illumina) with a target coverage of 150× for tumour 
samples and 70× for matched normal (MSKCC Center for Molecular Oncology). 
Sequence data were demultiplexed using CASAVA, and after removal of  adaptor 
sequences using cutadapt (v1.6), reads were aligned to the reference human 
genome (hg19) using the Burrows–Wheeler Alignment tool (bwa mem v0.7.12). 
Duplicate-read removal, InDel realignment and base quality score recalibration 
were performed using the Genome Analysis Toolkit (GATK) according to GATK 
best practices, as described previously6. Variants were identified on processed data 
using Mutect, Mutect rescue (SNPs) and HaplotypeCaller (insertions/ deletions). 
A mean unique sequence coverage of 167.45× was achieved for tumour samples 
and 84.75 for normal samples. All MUC16 mutations were manually reviewed by 
3 investigators using the Integrated Genomics Viewer v2.3.72. Whole-genome and 
whole-exome sequencing for ICGC21 patients has been described previously. For 
all ICGC and rapid autopsy samples, BAM files were re-processed and mutations 
identified as per the above outlined MSKCC protocol. Depth of sequencing for the 
rapid autopsy samples ranged from 150× to 250× .
HLA typing. HLA typing for patients with PDAC was performed in silico using the 
tool Short Oligonucleotide Analysis Package (SOAP)-HLA (http://soap.genomics.
org.cn/SOAP-HLA.html).
Somatic mutation immunogenicity predictions. MSKCC pipeline. 
Immunogenicity of somatic mutations was estimated using a previously described 
bioinformatics tool called NASeek6. In brief, NASeek is a computational  algorithm 
that first translates all mutations in exomes to strings of 17 amino acids, for both 
the wild-type and mutated sequences, with the amino acid resulting from the 
mutation centrally situated. Second, it evaluates putative MHC class I binding 
for both wild-type and mutant nonamers using a sliding window method using 
NetMHC3.4 (http://www.cbs.dtu.dk/services/NetMHC/) for patient-specific HLA 
types, to generate predicted binding affinities for both peptides. NASeek finally 
assesses for similarity between nonamers that were predicted to be presented by 
patient-specific MHC class I. All mutations with binding scores below 500 nM are 
defined as neoantigens (Supplementary Table 1). As the MSKCC pipeline was, on 
average, more stringent with respect to the number of neoantigens identified (in 
comparison to the pVAC-Seq pipeline below), all neoantigen predictions were 
performed with the MSKCC pipeline unless otherwise specified.
pVAC-Seq pipeline. As an independent algorithm to identify neoantigens, we 
used the pVAC-Seq pipeline7 with the NetMHCpan binding strength predictor  
(< 500 nM binding strength). As recommended, we used the variant effect  predictor 
from Ensembl25 to annotate variants for downstream processing by pVAC-Seq.
Neoantigen fitness modelling. The fitness of a clone is defined as
=α α α
dN
dt
F N
where Nα is the effective population size of tumour clone α and Fα is the fitness of 
clone α . We assume that the fitness effects due to the immune system are separable 
from other tumour fitness effects; that is, = +α α αF F F
I0 , where αF
I  denotes the 
contribution to fitness due to selection on neoantigens and αF
0  denotes contribu-
tions from other factors, such as classical tumour driver mutations. Our model 
assumes the two components are separable, which is essentially equivalent to 
assuming that targeting of neoantigens is emanating largely from passenger muta-
tions. We test the hypothesis that, owing to T-cell-mediated immune recognition, 
for some tumours, the deleterious effects of immune pressure due to mutation- 
derived neoantigens can become a dominant fitness effect, either counteracting or 
substantially slowing the growth rate of the tumour.
In general, the predicted effective total tumour population size at time τ, 
denoted as n(τ), is
∑ ∑τ
τ
τ τ= = = +
α
α α
α
α α αn
N
N
X F X F F( ) ( )
(0)
(0) exp( ) (0) exp(( ) )I0
where =∑α αN N(0) (0)  is the initial total effective population size of all clones 
within the tumour, and =αX (0)  /αN N(0) (0) is the frequency of clone α . The initial 
frequency of clone α is the size of a clone estimated from a tumour’s  phylogenetic 
tree, using the PhyloWGS software package (https://github.com/morrislab/ 
phylowgs)26. For the tumours in our cohort there was not a discernable difference 
in the distributions of pancreatic cancer driver mutations across clones. As a result 
we assume ≈αF F
0
0. Therefore,
∑τ τ= τ
α
α αn X F( ) e (0) exp( )F
I0
We rank samples according to the value of n(τ), on the basis of their neoantigen– 
immune interactions only. This is equivalent to the assumption that τeF0  also does 
not vary as considerably across samples when compared with τ∑α α αX F(0) exp( )
I . 
As a result
∑τ τ∝
α
α αn X F( ) (0) exp( )
I
when considered across our cohort, and we use the immune component as a basis 
for ranking. Our hypothesis is that there are tumours in which typically ≤ | |αF F
I
0 , 
and the deleterious effects of neoantigen recognition sufficiently counterbalance 
the growth of the tumour. By ranking tumours according to n(τ), we therefore test 
whether tumours with the strongest deleterious effects owing to neoantigen fitness 
have better survival.
For a given neoantigen with sequence s we calculate R as the probability that 
neoantigen s is recognizable by the T-cell receptor repertoire. We do so by calcu-
lating the probability that a neoantigen sufficiently aligns to an epitope e from the 
IEDB via a thermodynamic model using the alignment score between the two 
peptides, | s, e| :
∑= − −−
∈
s eR Z k k a( ) exp[ ( , )]
e
1
IEDB
where a represents the horizontal displacement of the binding curve and k sets the 
slope of the curve at a. The partition function then becomes
∑= + − −
∈
s eZ k k a( ) 1 exp[ ( , )]
e IEDB
The set of known positive epitopes were derived from the IEDB, restricting the 
search to all human infectious disease, class I-restricted targets with positive 
immune assays (http://www.iedb.org/). As the peptides in IEDB can change over 
time, the version of IEDB used in our study is included (Supplementary Table 2). 
The alignments between all neoantigens and IEDB epitope sequences are found 
with the blastp algorithm using BLOSUM62 matrix (gap opening penalty = − 11, 
gap extension penalty = − 1). For the identified alignments the alignment scores 
are then computed with Biopython Bio.pairwise2 package (http://biopython.org).
The amplitude due to relative MHC dissociation constants between a neoanti-
gen and its wild-type counterpart is ≈ /A K Kd
WT
d
MT , approximated here by the
ratio of their inferred MHC binding affinities, which are inferred for neoantigens 
and their wild-type counterpart using NetMHC3.4 (http://www.cbs.dtu.dk/ 
services/NetMHC/) as described above. We use the standard cutoff for Kd
MT, the
mutant dissociation constant, used in the literature, that is <K 500 nMd
MT . For a
given neoantigen, the quantity A × R is referred to as the recognition potential of 
a neoantigen, and is a measure of neoantigen quality in regard to T-cell receptor 
recognition. Fitness due to T-cell-mediated neoantigen recognition within a clone 
is defined as
=− ×α
∈ α 
F A Rmax ( )I
i
i i
Clone
where i is an index running over neoantigens within a clone; that is, within a clone α, 
the maximal product of the amplitude Ai and the recognition probability Ri for a 
neoantigen. As an alternative hypothesis, fitness in the neoantigen load hypo thesis 
is defined as =−α αF L ,
I  where Lα is the simple number of neoantigens in clone α. 
For all cases, we computed the neoantigen load without clonal phylogeny, which 
was the standard benchmark, and the neoantigen load with clonal phylo geny, by 
taking into account the effective size of clones in which neoantigens were 
 contained. We also compared our results to those obtained using the wild-type 
recognition potential alone—in which case our MHC amplitude was 1—and 
the fitness model without clonality, which essentially just scores the best  neoantigen 
across the tumour.
We split samples by the median value of the cohort, with samples below this 
value designated as a low fitness group (neoantigen qualityhigh group), and those 
above as a high fitness group (neoantigen qualitylow group). We then compared 
survival for high- versus low-quality groups, expecting high-quality tumours to 
be related to longer patient survival times. Our model has three parameters: a, k 
and τ. We observe significant separation of patients at a sufficiently steep proba-
bility binding function; we therefore set the slope parameter k = 1. We report  values 
for the shift and time parameters, a and τ, which optimized survival, as quantified 
by the log-rank test score using the lifelines software package (https://lifelines.
readthedocs.io/en/latest/). To test the stability of this choice, we derived the optimal 
value for subsampled datasets, with subsampling frequencies of 0.5, 0.7, and 0.9. 
The optimal parameters obtained on the full dataset, a = 26 and τ∈ . .[0 02, 0 04]
were the most frequent choice for all subsampling frequencies (as shown on the 
distribution of optimal parameters in Extended Data Fig. 7a).
We repeated the same analysis on the larger ICGC cohort with 166 patients. The 
optimal parameters obtained on the full dataset were a = 23 and τ∈ . .[0 19, 0 21]; 
however the optimum depended only marginally on τ, raising significant patient 
segregation for a very broad interval of values (in particular at τ∈ . .[0 02, 0 04], 
optimal for the MSKCC cohort, we obtain P < 0.01, see Extended Data Fig. 7a). 
We observe that the horizontal displacement parameter a is lower than in the 
MSKCC cohort. We attribute this trend to the difference in the survival time dis-
tribution in the two cohorts and the MSKCC cohort containing extreme LTSs, with 
probably ‘higher quality’ neoantigens.
In vitro T-cell assays. Fresh blood was collected from seven PDAC LTSs whose 
tumours were identified on the basis of whole-exome sequencing and in silico 
 predictions to harbour neoantigens. PBMCs were  isolated by density centrifu-
gation over Ficoll-Paque Plus (GE Healthcare). Peptides were generated for 
immunodominant neoantigens as predicted by the  neoantigen quality algo-
rithm (the neoantigen with the maximum quality score within a tumour, driven 
by maximal TCR recognition probability was defined as the immunodominant 
neoantigen), MUC16 neoantigens, and the corresponding wild-type non-
amers (Peptide 2.0, Supplementary Table 2). In vitro peptide  stimulation was 
performed as described with minor modifications6. In brief, 1 × 106 PBMCs 
were cultured with mutant or wild-type peptides (10 μ g ml−1) on day 1. IL-2 
(50 U ml−1) and IL-15 (10 ng ml−1) were added on day 2 and every subsequent 2–3 
days. Mutant and wild-type peptides were added to respective cultures on day 7, 
and day 14 for second and third rounds of restimulation. On day 21, cells were 
restimulated in the presence of peptide for 5 h and cells were subsequently stained 
as per the manufacturer’s instructions or subject to sequencing. A peptide pool of 
23 class-I-restricted viral peptides from human cytomegalovirus and influenza 
virus (CEF, Cellular Technology Limited) served as a positive control (data not 
shown). Normalized expansion on day 21 of culture was defined as (absolute CD8+ 
T-cell expansion day 21 − absolute CD8+ T-cell expansion day 0)/(absolute CD8+
T-cell expansion day 0).
Flow cytometry. Fresh blood and tumour samples from six individual patients 
undergoing elective surgery at MSKCC were collected. Informed  consent was 
obtained according to a MSKCC Institutional Review Board-approved protocol. 
Blood was drawn at the time of surgery, and PBMCs were isolated by density 
centrifugation over Ficoll-Paque Plus (GE Healthcare). Tumour and draining 
lymph-node tissues were processed immediately after removal from the patient 
and single-cell suspensions were prepared. To assess whether T cells bind in silico
predicted neoantigen–HLA complexes, T cells of PBMCs from HLA-specific 
healthy donors (Precision For Medicine) were assessed for binding to MUC16-
neoantigen–MHC multimers. MUC16-MHC–fluorescein isothiocyanate (FITC) 
multimers were designed to HLA-B0801 (Immudex) with nonamer peptide
sequences derived based on mutated MUC16 sequences identified on whole-ex-
ome sequencing that were in silico predicted to be immunogenic. Single-cell
PBMC suspensions were surface stained for anti- human CD45, CD3, CD56, 
CD8, CD4, CD107a, and MHC-multimers according to the manufacturer’s
instructions. Human-specific antibodies used in all flow- cytometric phenotyp-
ing included CD45 (clone HI30, BioLegend), CD3 (clone OKT3, BioLegend), 
CD4 (clone SK3, BD Biosciences), CD8 (clone SK1, BioLegend), CD56 (clone 
B159, BD Biosciences), CD69 (clone FN50, BD Biosciences), CD19 (clone
SJ25C1, BD Biosciences), PD1 (clone MIH4, BD Biosciences), CD45RA (clone 
HI100, BD Biosciences), CD45 RO (clone UCHL1, BD Biosciences), CD56 
(clone B159, BD Biosciences) and CD107a (clone H4A3, BD Biosciences). Flow 
cytometry was performed on an LSRFortessa (BD Biosciences) and data were 
 analysed using FlowJo Software (Tree Star).
Plasmids and transfection. phrGFP II-C vector (Stratagene) expressing human
wtMUC16c354N206–GFP fragment was a gift from the D. Spriggs laboratory. A point
mutation at position R15C in the C-terminal portion of wtMUC16 was introduced 
using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and 
validated by sequencing. HEK293T cells were transiently transfected with phrGFP 
II-C vector (empty vector), wtMUC16c354N206–GFP, mtMUC16R16C–GFP using 
Lipofectamine 3000 (Invitrogen) according to the manufacturer’s  instructions. 
Protein extracts from transiently transfected cells were analysed by western blot 
(clone 4H11, anti-MUC16-carboxy-terminal monoclonal antibody27) and β -actin–
HRP antibody (Sigma Aldrich). Transfected cells were also analysed by immuno-
cytochemistry (clone 4H11).
Statistics. Comparisons between two groups were performed using an unpaired 
two-tailed Mann–Whitney U-test (unpaired samples), a paired two-tailed Mann–
Whitney U-test (paired samples), and a two-tailed Student’s t-test (normally dis-
tributed parameters). Multiple samples were compared using a Kruskal–Wallis 
test (non-grouped) and ANOVA with Tukey’s post-test for multiple comparisons 
(grouped). Survival curves were compared using a log-rank test (Mantel–Cox). 
Categorical variables were compared using a χ2 test. All comparison groups had
equivalent variances. Specific clonal expansion on day 21 compared to day 0 
(> 2-fold expansion by Fisher’s exact test and Storey’s Q value for false discovery rate)
was assessed by TCR Vβ sequencing. In Fig. 3d, we tested whether the  number of 
clones expanding under more than one condition (mutant, cross reactive, tumour) is 
significantly different than that which would be observed by chance using Poisson-
family saturated log-linear models with the canonical link function and the corre-
sponding P values for the third-degree term in these models. We used a hypothetical 
value of 107 for the total number of clones in the blood for this calculation. The glm
function in R version 3.4 was used for fitting these models. P < 0.05 was considered
to be statistically significant. Data analysis was performed using statistical software 
(Prism 7.0, GraphPad software; Cox regression using STATA 13.1).
Data availability. Data presented in this study can be downloaded from https://
dcc.icgc.org/repositories under the identifier PACA-AU. Transcriptomic data are 
available under Gene Expression Omnibus (GEO) accession number 89997. Source 
Data are provided for all experiments, including Figs 1b, c, e, 3a–d, 4a–e, and 
Extended Data Figs 2a–c, 3a, 3c, 3e, 4c, 6b, 8e, 9a–f, 10a. All other data are available
from the corresponding author upon reasonable request.
Code availability. The data (Supplementary Table 1), the computational algorithm 
and software used, (Extended Data Fig. 7), and the source code (Supplementary 
Data 1) allowing for reproduction of the neoantigen quality evaluation in this 
manuscript are included as indicated above.
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Clinicopathologic characteristics of patients in TCR sequencing cohort.
Clinicopathologic characteristics of patients in matched primary and 
metastatic tumor cohort.
Variable Short Term (n = 45)
n (%)
Long Term (n = 51) 
n (%)
P- value
Gender
Male 24 (53) 26 (51) 0.84
Female 21 (47) 25 (49)
Age
Median (Range) 78 (54-91) 74 (38-95) 0.33
Tumor Location
Head 32 (71) 37 (73) 1
Body/Tail 13 (29) 14 (27)
Procedure
Distal Pancreatectomy 13 (29) 13 (25) 0.93
Pancreaticoduodenectomy 31 (69) 37 (73)
Total Pancreatectomy 1 (2) 1 (2)
Pathological Stage
I 0 (0) 2 (4) 0.09
II 38 (84) 47 (92)
III 4 (9) 2 (4)
IV* 3 (7) 0 (0)
pT
1 0 (0) 0 (0) 0.35
2 0 (0) 2 (4)
3 42 (96) 47 (92)
4 3 (4) 2 (4)
pN
0 11 (24) 21 (41) 0.13
1 34 (76) 30 (59)
pM
0 42 (93) 51 (100) 1
1* 3 (7) 0 (0)
Margin
Positive 8 (18) 2 (4) 0.04
Negative 37 (82) 49 (96)
Adjuvant Treatment
Yes 24 (53) 42 (82) 0.008
No 20 (45) 9 (18)
Unknown 1 (2) 0 (0)
Variable Short Term (n = 15)
n (%)
Long Term (n = 15)
n (%)
P- value
Gender
Male 8 (53) 5 (33) 0.46
Female 7 (47) 10 (67)
Age
Median (Range) 76 (54-84) 65 (51-95) 0.20
Tumor Location
Head 10 (67) 12 (80) 0.69
Body/Tail 5 (33) 3 (20)
Procedure
Distal Pancreatectomy 5 (33) 3 (20) 0.69
Pancreaticoduodenectomy 10 (67) 12 (80)
Pathological Stage
I 0 (0) 0 (0) 0.34
II 12 (80) 14 (93)
III 1 (7) 1 (7)
IV* 2 (13) 0 (0)
pT
1 0 (0) 0 (0) 1
2 0 (0) 0 (0)
3 13 (87) 14 (93)
4 2 (13) 1 (7)
pN
0 5 (33) 6 (40) 1
1 10 (67) 9 (60)
pM
0 13 (87) 15 (100) 0.48
1* 2 (13) 0 (0)
Margin
Positive 4 (27) 1 (7) 0.33
Negative 11 (73) 14 (93)
Adjuvant Treatment
Yes 10 (67) 13 (87) 0.36
No 4 (26) 2 (13)
Unknown 1 (7) 0 (0)
Variable Short Term (n = 30) 
n (%)
P- value
Gender
Male 17 (57) 12 (40) 0.30
Female 13 (43) 18 (60)
Age
Median (Range) 73 (45-91) 75 (54-95) 0.28
Tumor Location
Head 17 (57) 23 (77) 0.17
Body/Tail 13 (43) 7 (23)
Procedure
Distal Pancreatectomy 13 (43) 7 (23) 0.17
Pancreaticoduodenectomy 17 (57) 23 (77)
Pathological Stage
I 0 (0) 2 (7) 0.17
II 26 (87) 27 (90)
III 1 (3) 1 (3)
IV* 3 (10) 0 (0)
pT
1 0 (0) 2 (7) 0.31
2 0 (0) 0 (0)
3 28 (93) 27 (90)
4 2 (7) 1 (3)
pN
0 14 (47) 17 (57) 0.61
1 16 (53) 13 (43)
pM
0 28 (93) 30 (100) 0.49
1* 2 (7) 0 (0)
Margin
Positive 1 (3) 2 (7) 1
Negative 29 (97) 28 (93)
Adjuvant Treatment
Yes 18 (60) 26 (86) 0.04
No 9 (30) 2 (7)
Unknown 3 (10) 2 (7)
Long Term (n = 30) 
n (%)
Variable Short Term (n = 32)
n (%)
Long Term (n = 26)
n (%)
P- value
Gender
Male 15 (47) 8 (31) 0.28
Female 17 (53) 18 (69)
Age
Median (Range) 73 (48-91) 75 (51-95) 1
Tumor Location
Head 18 (56) 21 (81) 0.06
Body/Tail 14 (44) 5 (19)
Procedure
Distal Pancreatectomy 13 (41) 5 (19) 1
Pancreaticoduodenectomy 19 (59) 21 (81)
Pathological Stage
I 0 (0) 1 (4) 0.29
II 28 (88) 24 (92)
III 1 (3) 1 (4)
IV* 3 (9) 0 (0)
pT
1 0 (0) 1 (4) 0.5
2 0 (0) 0 (0)
3 29 (91) 24 (92)
4 3 (9) 1 (4)
pN
0 9 (28) 11 (42) 0.28
1 23 (72) 15 (58)
pM
0 30 (94) 26 (100) 0.25
1* 2 (6) 0 (0)
Margin
Positive 5 (16) 3 (12) 0.72
Negative 27 (84) 23 (88)
Adjuvant Treatment
Yes 22 (63) 24 (92) 0.08
No 9 (28) 2 (8)
Unknown 1 (9) 0 (0)
Variable MUC16 
Neoantigenic 
(n = 2), n (%) 
Non- MUC16 
Neoantigentic 
(n = 2), n (%) 
P- value
Gender
Male 0 (0) 1 (50) 1
Female 2 (100) 1 (50)
Age
Median (Range) 71 (57-85) 52 (50-54) 0.31
Pathological Stage
I 0 (0) 0 (0) 1
II 0 (0) 0 (0)
III 1 (50) 0 (0)
IV 1 (50) 2 (100)
Chemotherapy
Yes 2 (100) 1 (50) 1
No 0 (0) 1 (50)
Long Term (n = 7)
n (%)
Gender
Male 1 (14)
Female 6 (86)
Age
Median (Range) 73 (60-88)
Tumor Location
Head 4 (57)
Body/Tail 3 (43)
Procedure
Distal Pancreatectomy 3 (43)
Pancreaticoduodenectomy 4 (57)
Pathological Stage
I 1 (14)
II 6 (86)
III 0 (0)
IV 0 (0)
pT
1 1 (14)
2 0 (0)
3 6 (86)
4 0 (0)
pN
0 5 (71)
1 2 (29)
pM
0 7 (100)
1 0 (0)
Margin
Positive 1 (14)
Negative 6 (86)
Adjuvant Treatment
Yes 7 (100)
No 0 (0)
Unknown 0 (0)
Recurrence and Survival Recurrence Survival (years)
Patient 1 No 10.5
Patient 2 No 9.5
Patient 3 No 11.5
Patient 4 No 11.8
Patient 5 Yes 7.3
Patient 6 Yes 11.8
Patient 7 No 7.7
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Extended Data Figure 1 | Clinicopathological characteristics of the 
MSKCC cohort. a, Overall survival and patient overlap of short- and 
long-term survivors in tissue microarray, whole-exome sequencing, 
TCR Vβ sequencing, and bulk tumour transcriptomic profiling cohorts. 
b–g, Clinicopathological characteristics of patients in tissue microarray, 
transcriptome, TCR sequencing, whole-exome sequencing, matched 
primary–metastatic, and very long-term survivor cohorts. In b–e, the 
asterisk indicates three patients with metastases noted on final pathology 
(one liver metastasis, one metastasis to small bowel/mesentery, one 
splenic metastasis). n is the number of biologically independent samples 
in individual patients. P values were determined using a log-rank test 
(a) and a two-sided Fisher’s exact test (gender, tumour location, pN, pM, 
margin, chemotherapy), a two-sided χ2 test (procedure, pathological stage, 
pT, adjuvant treatment) and an unpaired, two-tailed Student’s t-test (age)
(b–g).
cVariable 
Univariate Multivariate 
Hazard 
Ratio 
95% CI P-Value Hazard 
Ratio 
95% CI P-Value 
Adjuvant chemotherapy 0.7 0.4–1.3 0.4 0.7 0.3–1.3 0.3 
Pathologic stage 2.0 0.8–4.7 0.1 - - - 
Margin 1.6 0.8–3.3 0.1 - - - 
CD3–CD8-granzyme-B density 0.4 0.2–0.8 0.004 0.4 0.2–0.8 0.007 
P = 0.004
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Extended Data Figure 2 | See next page for caption.
Extended Data Figure 2 | Long-term survivors of PDAC display 
enhanced intratumoural T-cell immunity. a, Left: representative 
sequential immunohistochemical staining of a single short-term and 
a single long-term core tumour section. Sections bounded by black 
rectangles in the 100× panels are magnified to 275× in the panels 
immediately to the right for each core section. Top right: representative 
merged images of multiplexed immunohistochemistry are shown.  
The red rectangular sections are enlarged to 50× . CK19 was used to stain 
tumour cells. The arrows indicate CD3+CD8+granzyme B+ T cells. Middle 
right: immunofluorescent quantification of CD8+ and CD4+ cells in 
tumour tissue microarrays of short- and long-term survivors. Slides used 
were cut from separate sections of the block as those used for sequential 
immunohistochemistry (in a and Fig. 1b). Bottom right: quantification 
of multiplexed immunophenotyping as shown in a (left and top right). 
All immunofluorescent and immunohistochemical staining was repeated 
independently in triplicate for each patient. In a, short term n = 45, long 
term n = 51. b, Bulk tumour transcriptomic immune profiling in short- 
and long-term survivors. Dendritic-cell signature genes include CCL13, 
CCL17, CCL22, PPFIBP2, NPR1, HSD11B1 and CD209 (also known as 
DC-SIGN)3. c, Flow-cytometric gating strategy to phenotype human
T cells (n = 7). The first plot is pre-gated on live cells, followed by CD45+
and CD3+CD56− cells. Values indicate the percentage of cells within
the red boxes, and are gated based on isotype controls. d, Top: overall
survival of patients who did or did not receive adjuvant chemotherapy 
(adjuvant chemotherapy+/− respectively, top left), and of patients with 
tumours harbouring more or fewer than the median number of CD3-
CD8-granzyme B triple-positive cells (CD3-CD8-granzyme Bhi/low
respectively, top right). Overall survival of all four groups is shown in the 
bottom panels. The table shows univariate and multivariate Cox regression 
analysis of clinicopathological features, adjuvant chemotherapy, and CD3-
CD8-granzyme B density associations with overall survival. Horizontal 
bars indicate median values, error bars represent the s.e.m. n is the number 
of biologically independent samples in individual patients. P values were
determined using a two-tailed Mann–Whitney U-test (a, b), a one-way
ANOVA (c) and a log-rank test (d).
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Extended Data Figure 3 | Neoantigen quantity and CD8+ T-cell 
infiltrate identify long-term pancreatic cancer survivors. a, Left: 
number of nonsynonymous, missense and neoantigenic mutations per 
patient in the MSKCC cohort. The tick marks on the x axis correspond 
to individual tumours. Right: oncoprint demonstrating the frequency 
of oncogenic driver-gene mutations in the MSKCC cohort. b, Overall 
survival of patients with tumours harbouring more than the median 
number of neoantigens (neoantigenhi), and greater than the median 
intratumoural T-cell repertoire polyclonality (polyclonalhi), compared 
to all other patients (rest). Neoantigens were determined using the 
MSKCC (top) and the pVAC-Seq (bottom) neoantigen prediction 
pipelines. c, Left: number of neoantigens per tumour, as determined by 
the MSKCC and pVAC-Seq neoantigen calling pipelines. Tick marks on 
the x axis correspond to individual tumours. Right: correlation matrix 
of neoantigens as determined by the MSKCC and pVAC-Seq neoantigen 
calling pipelines. The solid red line indicates the line of best fit, dotted 
lines indicate 95% confidence intervals. d, Top: overall survival of patients 
with tumours harbouring more or fewer than the median number of 
neoantigens (neoantigenhi/low) and CD3-CD8 double-positive cells (CD3-
CD8hi/low), compared to all other patients (rest) (top left). Patients who 
did or did not receive adjuvant chemotherapy (adjuvant chemotherapy+/−, 
respectively) (top right), and all four groups (bottom) are also shown. 
The table shows univariate and multivariate Cox regression analysis of 
the associations of clinicopathological features, adjuvant chemotherapy, 
and neoantigen-CD3-CD8 number with overall survival. e Distribution 
of tumours with high- and low-quality neoantigens in neoantigenhi 
CD3-CD8hi long-term pancreatic cancer survivors compared to all other 
patients (rest). n is the number of biologically independent samples in 
individual patients. P values were determined using a log-rank test (b, d) 
and a χ2 test (e).
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Extended Data Figure 4 | Unique genomic features alone do not 
identify long-term survivors of PDAC. a, Overall survival of patients 
with tumours harbouring more or fewer than the median number of 
neoantigens (neoantigenhi/low), CD3-CD8 double-positive cells (CD3-
CD8hi/low), polyclonality (polyclonalhi/low), mutations (mutationhi/low), 
and CD4 single positive cells (CD4hi/low). b, Oncoprint demonstrating 
no difference in the frequency of oncogenic driver mutations in short- 
and long-term tumours. c, No difference was found in the number of 
nonsynonymous, missense, and immunogenic mutations (neoantigens) 
in short- and long-term PDAC tumours. d, Overall survival stratified 
by mutations in ARID1A, KRASQ61H, RBM10 and MLL-related genes 
(KMT2A, KMT2B, KMT2C and KMT2E (also known as MLL, MLL2, 
MLL3 and MLL5, respectively)). Horizontal bars indicate median values. 
n is the number of biologically independent samples in individual patients. 
P values were determined using a log-rank test (a, d).
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Extended Data Figure 5 | Neoantigen immune fitness models.  
a, Comprehensive flowchart of neoantigen quality identification pipeline. 
Software programs used for each step are indicated in italicized text. 
Mathematical formulae for the calculation of individual components of 
neoantigen quality are defined in the Methods. All software components 
of the pipeline are published and/or publicly available. b, Top: schematic of 
neoantigen immune fitness models. Each circle represents a tumour clone 
in an evolutionary tree. Clones in both models are identical with respect 
to the number of mutations and neoantigens. The numbers represent 
hypothetical neoantigens gained in a successive tumour clone. Shades 
of red indicate the immunogenicity of each clone, as ascribed by the 
two models, namely neoantigen quality or neoantigen quantity. Bottom: 
parameters defining the quality score in the quality model (1)–(3). In 
(1), amino acid sequences of a hypothetical wild-type epitope, tumour 
neoepitope, and a homologous microbial epitope are shown. Yellow 
highlights the changing amino acid between the wild-type and the tumour 
sequence as a consequence of a tumour-specific mutation. The amino 
acids in red indicate homology between the tumour neoepitope and the 
microbial epitope.
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Extended Data Figure 6 | Neoantigen quality is independently 
prognostic of survival. a, Top: overall survival of patients whose tumours 
displayed high compared to low neoantigen quality (neoantigen  
qualityhi/low) (left), and overall survival of patients who did or did not 
receive adjuvant chemotherapy (right). Bottom: overall survival of all four 
groups. Neoantigen quality defined by pipeline and schema as defined 
in Extended Data Fig. 5a, b. The table shows univariate and multivariate 
Cox regression analyses of the associations of clinicopathological features, 
adjuvant chemotherapy and neoantigen quality with overall survival.  
Data include all patients in the whole-exome sequencing MSKCC cohort. 
b, Number of nonsynonymous, missense and neoantigenic mutations per 
patient in the ICGC cohort (n = 166). c, Top: overall survival of patients 
in the ICGC cohort whose tumours displayed high compared to low 
neoantigen quality (neoantigen qualityhi/low) (left), and overall survival 
of patients in the ICGC cohort stratified by adjuvant chemotherapy 
administration (right). Bottom: overall survival of all four groups. 
Neoantigen quality defined by pipeline and schema as defined in Extended 
Data Fig. 5a, b. The table shows univariate and multivariate Cox regression 
analyses of the associations of clinicopathological features, adjuvant 
chemotherapy and neoantigen quality with overall survival in the ICGC 
cohort. Data on adjuvant chemotherapy is included for patients whose 
treatment status was available. n is the number of biologically independent 
samples in individual patients. P values were determined using a log-rank 
test (a, c).
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Extended Data Figure 7 | Stability of neoantigen quality model 
parameters on subsampled cohorts and prognostic dependence  
of neoantigen quality on infectious disease-derived peptides.  
a, b, Parameters of the neoantigen fitness quality model for the MSKCC (a) 
and the ICGC (b) cohorts. Left: log-rank test score landscape as a function 
of the model parameters (the horizontal alignment score displacement a,  
and the characteristic time τ); the significance of the score is denoted in 
the legend. Right: two-dimensional histograms showing distributions of 
optimal parameters obtained on subsampled datasets with 50, 70, and 
90% of patients left, over 500 iterations of subsampling at each frequency. 
c, Overall survival of patients in the MSKCC and ICGC cohorts; whole 
tumours displayed high compared to low neoantigen quality (neoantigen 
qualityhi/low). Neoantigen quality was calculated using alignment to 
immunogenic infectious disease-derived IEDB peptides (microbial 
peptides) or using alignment to immunogenic non-infectious disease-
derived allergy or autoimmune peptides in the IEDB database (non-
microbial peptides). n is the number of biologically independent samples 
in individual patients. P values were determined using a log-rank test (c).
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Extended Data Figure 8 | Predicted MUC16 neoantigens are recognized 
by the human TCR repertoire. a, PBMCs pulsed with no peptide, wild-
type control peptide, cross-reactive peptide or high-quality neopeptide 
(mutant). Representative gating strategies for CD8+ T-cell expansion and 
degranulation are shown. b, PBMCs pulsed with no peptide, wild-type 
control peptide, and MUC16 neopeptides (mutant). Representative gating 
strategies for CD8+ T-cell expansion are shown. c, Representative gating 
strategy to identify CD8+ T cells in peripheral blood of healthy donors 
(top panel). Identification of CD8+ T cells in healthy donors reactive to 
unique MUC16 neoepitopes predicted to bind to the B* 0801 HLA-allele, 
using MUC16-neoepitope–HLA multimers. Quantification of all healthy 
donors (neoepitope no. 1, 2, n = 5) is shown (right). Multimer staining 
is shown on the x axis, CD8 is shown on the y axis. Peptide information 
is provided in Supplementary Table 3. n is the number of biologically 
independent samples in individual patients. Horizontal bars indicate 
median values, error bars represent the s.e.m. P values were determined 
using a one-way ANOVA (c).
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Extended Data Figure 9 | See next page for caption.
Extended Data Figure 9 | Long-term survivors do not display 
differences in MUC16 mutations, transcriptional regulators or 
downstream targets of MUC16, or differences in other mucins and 
tissue expression antigens. a, The frequency of MUC16 mutations in 
short- and long-term PDAC tumours. Lollipop plot showing the location 
of MUC16 mutations and neoantigens in short- and long-term survivors 
of pancreatic cancer. b, Expression of bulk tumour MUC16 mRNA (left) 
and protein (middle) by immunohistochemistry. Immunohistochemical 
staining was repeated independently in triplicate for each patient. 
Right: MUC16 mutant allele frequency in non-hypermutated tumours 
with MUC16 mutations. c, Left: frequency of patients with MUC16 
neoantigens in MSKCC and ICGC cohorts. Middle: frequency of patients 
with neoantigens in genes recurrently harbouring neoantigens in > 5% of 
patients in both MSKCC and ICGC cohorts. Right: genes most frequently 
harbouring neoantigens in the MSKCC cohort as determined by pVAC-
Seq. Frequency of patients (y axis) and raw numbers (above bar graphs) 
are indicated. d, mRNA expression of transcriptional activators of MUC16 
(top left), mediators implicated in MUC16-dependent tumour progression 
(top right), and mRNA (bottom left) and protein (bottom right) levels of 
tissue expression antigens MUC1, MUC4, WT1, mesothelin and annexin 
A2 in short- and long-term tumours. WT1 protein was undetectable in 
both short- and long-term survivors. n = 15 per group in top left, top right, 
and bottom left; short term n = 45, long term n = 51 in bottom right.  
e, MUC16 mRNA and protein expression in MUC16 non-mutated  
(WT; n = 18 (top), n = 20 (bottom)) and mutated (mutant; n = 10 (top), 
n = 9 (bottom)) tumours. f, TCR Vβ sequencing of T-cell product 
following the pulse of peripheral blood T cells with MUC16 neopeptides 
as in Fig. 4e. Brown open circles indicate stable or contracted clones 
with mutant neopeptide; blue open circles indicate expanded clones 
with mutant neopeptide; red solid circles indicate expanded clones with 
mutant neopeptide detected in archival primary tumours. Arrows indicate 
clones in archival primary tumours with rank frequencies; Venn 
diagrams show clonal overlap in respective compartments. Horizontal bars 
indicate median values, error bars represent the s.e.m. n is the number 
of biologically independent samples in individual patients. P values were 
determined using two-tailed Mann–Whitney U- and Student’s t-tests (b),  
a χ2 test (c) and as described in the Methods (f).
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Extended Data Figure 10 | See next page for caption.
Extended Data Figure 10 | MUC16 mutations do not alter tumour 
cell-intrinsic MUC16 protein expression. a, Representative 
immunohistochemical staining (left) and quantification (right) of MUC16 
expression in tissue microarrays of short- and long-term survivors of 
pancreatic cancer, as assessed using three independent anti-MUC16 
antibodies. Ab no. 1: clone EPSISR23, purchased from Abcam; Ab no. 2: 
polyclonal, purchased from Abcam ab133419; Ab no. 3: clone 4H1127. 
Each open circle represents the median expression of independent 
immunohistochemical staining performed in triplicate for each patient.  
b, Western blot (top) and immunocytochemistry (bottom) of 
untransfected (− ), empty vector (vector), MUC16 wild-type (MUC16 
WT) and MUC16 mutant (MUC16 R15C) HEK293 cells. The left blot 
was probed with anti-MUC16-specific antibody (clone 4H1127) and the 
right blot with anti-β -actin. The red rectangle indicates the MUC16-
specific band. All cells in the bottom panels were probed with anti-MUC16 
antibody (clone 4H1127). The inserted mutation was identical to a 
neoantigenic MUC16 mutation (detected in patient 1 shown in Extended 
Data Fig. 9a). Data are representative of two independent experiments 
with similar results. c, MUC16 immunohistochemistry on samples from 
two long-term survivors of pancreatic cancer with MUC16 neoepitopes 
in primary resected tumours. Areas in rectangular low-power fields are 
shown magnified in the right panels. Immunohistochemical staining 
was performed independently in triplicate for each patient in tissue 
microarrays, and confirmed with immunohistochemical staining on 
whole tumour sections (shown). Horizontal bars indicate median values, 
error bars represent the s.e.m. n is the number of biologically independent 
samples in individual patients. P values were determined using a two-
tailed Student’s t-test (a).
